4-Aminopyridine to Treat Skin Burns
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorJohn Elfar
About this trial
Many patients suffer from traumatic burns and current treatments do not increase the regenerative potential of either skin grafts or the remaining uninjured skin. There is a need to develop treatments to accelerate and improve healing of burn injuries. More research is needed to evaluate the role of 4-AP, a promising new agent with an excellent safety profile, on wound and burn healing. The investigational treatment will be used to test the hypothesis that 4-AP accelerates burn healing in traumatically burned patients.
Eligibility criteria
Qualifiers
Injured (burned) adults with a maximum severity of second-degree burns.
Burns involving at least 6cm2 of skin area
Acute burns within 7 days of injury
Cognitive ability to evaluate burn healing, report sensory and motor deficit during examination.
Disqualifiers
History of multiple sclerosis, stroke or any other diagnosed neurological disorder
History of hypersensitivity to AMPYRA® or 4-aminopyridine
Current use of aminopyridine medications, including other compounded 4-AP
Suspected renal impairment based on the Choyke questionnaire.
Trial design
Treatments tested in this trial
- Drug: 4-Aminopyridine
- Placebo
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
John Elfar
Lead sponsor
University of Arizona
Sponsor institution
Source ClinicalTrials.gov